These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23306341)

  • 1. Acute necrotizing pancreatitis associated with vildagliptin.
    Kunjathaya P; Ramaswami PK; Krishnamurthy AN; Bhat N
    JOP; 2013 Jan; 14(1):81-4. PubMed ID: 23306341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vildagliptin-induced acute pancreatitis.
    Girgis CM; Champion BL
    Endocr Pract; 2011; 17(3):e48-50. PubMed ID: 21324812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin-induced acute pancreatitis without enzyme elevation.
    Mungan Z; Attila T; Ünal Kabaoğlu Z; Vural M
    Turk J Gastroenterol; 2017 Nov; 28(6):514-517. PubMed ID: 29086719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho Y; Itoh H
    Diabet Med; 2013 Apr; 30(4):e149-50. PubMed ID: 23323612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
    Busch SJ; Hoffmann P; Sahota P; Johnson R; Kothny W; Meyer F; Foley JE
    Diabetes Obes Metab; 2013 Jan; 15(1):72-6. PubMed ID: 22882290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
    Schweizer A; Dejager S; Foley JE; Couturier A; Ligueros-Saylan M; Kothny W
    Diabetes Obes Metab; 2010 Jun; 12(6):485-94. PubMed ID: 20518804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
    Bunck MC; Poelma M; Eekhoff EM; Schweizer A; Heine RJ; Nijpels G; Foley JE; Diamant M
    J Diabetes; 2012 Jun; 4(2):181-5. PubMed ID: 22051153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S; Raccah D; Schweizer A; Dejager S
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin-induced acute lung injury: a case report.
    Ohara N; Kaneko M; Sato K; Maruyama R; Furukawa T; Tanaka J; Kaneko K; Kamoi K
    J Med Case Rep; 2016 Aug; 10(1):225. PubMed ID: 27520566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid induced by vildagliptin: a report of three cases.
    Béné J; Jacobsoone A; Coupe P; Auffret M; Babai S; Hillaire-Buys D; Jean-Pastor MJ; Vonarx M; Vermersch A; Tronquoy AF; Gautier S
    Fundam Clin Pharmacol; 2015 Feb; 29(1):112-4. PubMed ID: 24861252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
    Aouidad I; Fite C; Marinho E; Deschamps L; Crickx B; Descamps V
    JAMA Dermatol; 2013 Feb; 149(2):243-5. PubMed ID: 23426497
    [No Abstract]   [Full Text] [Related]  

  • 19. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
    Ligueros-Saylan M; Foley JE; Schweizer A; Couturier A; Kothny W
    Diabetes Obes Metab; 2010 Jun; 12(6):495-509. PubMed ID: 20518805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.